News | July 04, 2007

Gadolinium-Based MRI Contrast Agents Linked to Potentially Fatal Disease

July 5, 2007 –The U. S. Food and Drug Administration recently warned that a commonly used contrast agent used to improve MRI images has been linked to a potentially fatal disease and patients who have had an MRI Scan and been diagnosed with NSF/ NFD should review the latest FDA warnings, and Injury Claim Filing information at the NSF/NFD MRI Website.
Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. These contrast agents have been linked to nephrogenic systemic fibrosis (NSF) and nephrogenic fibrosing dermopathy (NFD). These potentially fatal diseases cause thickening of the skin and connective tissues that inhibits their ability to move and may result in broken bones. Other organs are at risk of thickening as well.

The Johnson Law Firm, a law firm that represents clients nationwide in cases against the manufacturers of defective medical products, announced that it has created an informational website for patients who have been diagnosed with NSF/NFD: http://www.lawyersforclients.com/nsf-nfd/index.php.

According to the FDA, patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing the debilitating and a potentially fatal disease, NSF. Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents. In addition, patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity. FDA first notified health care professionals and the public about the gadolinium-related risks for NSF in June 2006.

For more information: http://www.lawyersforclients.com/nsf-nfd/index.php

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...